Lilly
  • For Consumers
    • Getting Started
    • FAQ and Resources
  • House For Healthcare Providers
    • Bamlanivimab Antibody Playbook
    • Access
    • Dosage and Administration
      • Dosage and Administration
      • Infusion Resources
      • HCP Patient Guide
    • Clinical Data
    • FAQ and Resources
Ask Lilly

We're here to help.

Phone Call:
Lilly COVID Hotline
(1-855-545-5921)
Link Visit Lilly Medical (HCP)
Question Submit a Question
Expand contact lilly
Skip to main content

Dosage and Administration Overview

For full dosage and administration information, please see the Fact Sheet for Healthcare Providers.

Bamlanivimab injection (700 mg/20 mL)

Bamlanivimab is a sterile, preservative-free solution available as:

  • Injection: 700 mg/20 mL (35 mg/mL) in a single-dose vial.

The dosage of bamlanivimab in adults and pediatric patients (12 years of age and older weighing at least 40g) is bamlanivimab 700 mg.

No dosage adjustment is recommended in pediatric patients who weigh at least 40 kg and are 12 years of age and older. Bamlanivimab is not authorized for patients weighing less than 40kg or those less than 12 years of age.

Administer bamlanivimab as soon as possible after positive results of direct SARS-CoV-2 viral testing and within 10 days of symptom onset.

Bamlanivimab must be diluted and administered as a single IV infusion over at least 60 minutes.

bamlanivimab vial box

Recommended dilution and administration instructions for bamlanivimab

Drug Number of Vials Volume of Bamlanivimab Volume of 0.9% Sodium Chloride Total Volume for Infusion Maximum Infusion Rate Minimum Infusion Time
Bamlanivimab (700 mg/20 mL) Number of Vials: 1 Vial Volume of Bamlanivimab: 20 mL Volume of 0.9% Sodium Chloride: 250 mL Total Volume for Infusion: 270 mL Maximum Infusion Rate: 270 mL/hr Minimum Infusion Time: 60 Minutes
temp icon

Storage

This product is preservative-free and therefore, the diluted infusion solution should be administered immediately. If immediate administration is not possible, store the diluted bamlanivimab infusion solution for up to 24 hours at refrigerated temperature (2°C to 8°C [36°F to 46°F]) and up to 7 hours at room temperature (20°C to 25°C [68°F to 77°F]) including infusion time.

vial icon

Preparation

If refrigerated, allow the infusion solution to equilibrate to room temperature for approximately 20 minutes prior to administration. Remove one bamlanivimab vial (700 mg/20 mL) from refrigerated storage and allow to equilibrate to room temperature for approximately 20 minutes before preparation. Do not expose to direct heat. Do not shake the vial.

no shake icon

Handling of vial

Inspect bamlanivimab visually for particulate matter and discoloration. Bamlanivimab is a clear to opalescent and colorless to slightly yellow to slightly brown solution.

dilute icon

Dilution

Withdraw 20 mL bamlanivimab from one 20 mL vial and inject into an infusion bag containing 250 mL prefilled 0.9% Sodium Chloride Injection. Discard any product remaining in the vial. Gently invert IV bag by hand approximately 10 times to mix. Do not shake.

iv bag icon

Infusion

Gather the materials for infusion:

  • Polyvinyl chloride (PVC) or polyethylene (PE)-lined PVC infusion set.
  • Use of an in-line or add-on 0.20/0.22 micron polyethersulfone (PES) filter is strongly recommended.

Attach the infusion set to the IV bag. Prime the infusion set. Administer the entire infusion solution in the bag via pump or gravity over at least 60 minutes.

timer icon

Post-Infusion

Once infusion is complete, flush the tubing to ensure delivery of the required dose. Clinically monitor patients during administration and observe patients for at least 1 hour after infusion is complete. If the infusion must be discontinued due to an infusion reaction, discard any unused product. The use of closed system transfer devices (CSTDs), elastomeric pumps, and pneumatic transport with bamlanivimab has not been studied.

Infusion Resources

State, territorial, and local public health officials along with individual sites of care looking for assistance with operationalizing the administration of bamlanivimab may view the Bamlanivimab Antibody Playbook.

These short videos show a brief representation of the process to prepare the IV infusion of bamlanivimab and the administration of a prepared IV infusion. For further details regarding bamlanivimab as a treatment, please review the Fact Sheet for Healthcare Providers available on this website. These videos are not training videos and are for demonstration purposes only.

HCP-Patient Counseling Guide

This guide is intended to be used by healthcare professionals to inform their patients about treatment with bamlanivimab.

Download Patient Guide
infusion day guide

Bamlanivimab is authorized for use for treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization.

  • Bamlanivimab has not been approved, but has been authorized for emergency use by FDA.
  • Bamlanivimab is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of the bamlanivimab under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Limitations of Authorized Use

  • Bamlanivimab is not authorized for use in patients:
    • who are hospitalized due to COVID-19, OR
    • who require oxygen therapy due to COVID-19, OR
    • who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity.
  • Benefit of treatment with bamlanivimab has not been observed in patients hospitalized due to COVID-19. Monoclonal antibodies, such as bamlanivimab, may be associated with worse clinical outcomes in hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation.

Important Safety Information

There are limited clinical data available for bamlanivimab. Serious and unexpected adverse events may occur that have not been previously reported with bamlanivimab use.

Hypersensitivity Including Anaphylaxis and Infusion-Related Reactions

There is a potential for serious hypersensitivity reaction, including anaphylaxis, with administration of bamlanivimab. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and/or supportive therapy.

Infusion-related reactions have been observed with administration of bamlanivimab. Signs and symptoms of infusion related reactions may include:

  • fever, chills, nausea, headache, bronchospasm, hypotension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, dizziness.

If an infusion-related reaction occurs, consider slowing or stopping the infusion and administer appropriate medications and/or supportive care.

Limitations of Benefit and Potential Risk in Patients with Severe COVID-19

Benefit of treatment with bamlanivimab has not been observed in patients hospitalized due to COVID-19. Monoclonal antibodies, such as bamlanivimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation. See Limitations of Authorized Use.

Adverse Events

Adverse events reported in at least 1% of BLAZE-1 clinical trial participants on bamlanivimab 700 mg and placebo were Nausea (3% vs 4%), Diarrhea (1% vs 5%), Dizziness (3% vs 2%), Headache (3% vs 2%), Pruritus (2% vs 1%) and Vomiting (1% vs 3%).

Use in Specific Populations

Pregnancy
There are insufficient data on the use of bamlanivimab during pregnancy. Bamlanivimab should only be used during pregnancy if the potential benefit outweighs the potential risk for the mother and the fetus.

Breastfeeding
There are no available data on the presence of bamlanivimab in human or animal milk, the effects on the breastfed infant, or the effects on milk production. Breastfeeding individuals with COVID-19 should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.

Health care providers should review the Fact Sheet for information on the authorized use of bamlanivimab and mandatory requirements of the EUA. Please see the FDA Letter of Authorization, Fact Sheet for Healthcare Providers, and Fact Sheet for Patients, Parents and Caregivers (English) or Fact Sheet for Patients, Parents and Caregivers (Spanish).

BAM HCP ISI 09NOV2020

Fact Sheet for Healthcare Providers
Dear HCP Letter Correction of Drug Information: Preparation and Administration Instructions
Fact Sheet for Patients, Parents and Caregivers (English)
Fact Sheet for Patients, Parents and Caregivers (Spanish)
FDA Letter of Authorization
Terms of Use
Privacy Statement
Accessibility Statement
Sitemap
Ask Lilly

We're here to help.

Phone Call:
Lilly COVID Hotline
(1-855-545-5921)
Link Visit Lilly Medical (HCP)
Question Submit a Question

This site is intended for US healthcare providers only.

PP-BM-US-0029 12/2020 ©Lilly USA, LLC 2020. All rights reserved.

All product/company names shown herein are the trademarks of their respective owners.

Terms of Use Privacy Statement Accessibility Statement Sitemap
Lilly